Medicinova Stock Price, News & Analysis

MediciNova, Inc. has announced a modification to its contract with BARDA to repurpose MN-166 (ibudilast) as a potential medical countermeasure against chlorine gas-induced lung damage. The contract extension lasts until May 31, 2023. MN-166, a small molecule compound, is in late-stage clinical development for various neurodegenerative diseases and is being evaluated for ARDS. MediciNova is focused on developing novel therapies for inflammatory and neurodegenerative diseases, with MN-166 currently in Phase 3 trials for ALS and DCM.

MediciNova, Inc. announced research findings from the glioblastoma clinical trial MN-166-GBM-1201, presented by Dr. Justin Lathia at the 20th Annual World Congress of SBMT. The study analyzed tumor tissues to identify predictors of treatment response to MN-166 and temozolomide. Results showed that responders had lower CD3+ T cell percentages and trends in CD74 expression compared to non-responders. Dr. Lathia highlighted MN-166's potential in enhancing CD3+ infiltration in glioblastoma patients. Chief Medical Officer Kazuko Matsuda noted the significance of these findings in addressing the challenges of glioblastoma treatment.

MediciNova has received authorization from Health Canada to initiate a multi-center, randomized clinical trial for MN-166 (ibudilast) targeting Long COVID treatment, under the RECLAIM trial. This Phase 2/3 trial aims to evaluate various therapies, including MN-166, with about 800-1000 patients expected to participate across Canada. The study will monitor improvements in patients' physical health over a 6-month period. This development highlights a significant unmet medical need for effective Long COVID interventions, potentially enhancing MediciNova's pipeline focused on inflammatory and neurodegenerative diseases.

MediciNova, Inc. has completed enrollment in a Phase 2b clinical trial of MN-166 (ibudilast) aimed at treating alcohol use disorder (AUD). This trial, funded by the National Institute on Alcohol Abuse and Alcoholism, includes 102 participants who will take MN-166 or a placebo over 12 weeks. The primary goal is to evaluate the reduction in heavy drinking days. Results from recent studies suggest MN-166 is a safe, promising treatment for AUD. The company is anticipating topline results following participant follow-up.

MediciNova announced the completion of enrollment in its Phase 2 clinical trial of MN-166 (ibudilast) for glioblastoma at Dana-Farber Cancer Institute. This trial includes a dose-escalation phase to determine safety and a fixed-dose phase to evaluate efficacy combined with temozolomide (TMZ). Preliminary results will be revealed at the 20th Annual World Congress of SBMT from February 16-19, 2023. Chief Medical Officer, Kazuko Matsuda, expressed optimism about potential predictors of treatment response and indicated further findings will be shared post-conference.

MediciNova has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application regarding MN-001 (tipelukast) and its metabolite MN-002, aimed at treating scleroderma/systemic sclerosis.

This patent is expected to expire no earlier than June 2035 and covers various administration forms and dosing frequencies. The CMO believes this patent could enhance the value of MN-001. The compound is in clinical development for several conditions, including NASH and IPF, with positive results in previous trials.

MediciNova, Inc. has received a Notice of Allowance from the Brazilian Patent and Trademark Office for a patent covering MN-001 (tipelukast) and MN-002, aimed at treating hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. This patent is expected to expire no earlier than July 2034. The allowed claims encompass uses for reducing triglycerides, cholesterol, and LDL levels, supporting various dosage forms. Clinical data indicates MN-001 shows significant triglyceride reduction in patients with hypertriglyceridemia and diabetes. A new Phase 2 trial is ongoing to further assess its effectiveness.

MediciNova has completed a Phase I clinical trial of MN-166 (ibudilast), showing a favorable safety and tolerability profile in healthy volunteers. The intravenous (IV) formulation was well tolerated, with no concerning adverse events reported. This formulation targets inflammatory disorders such as acute respiratory distress syndrome (ARDS) and offers a treatment option for hospitalized patients unable to take oral medication. The company is seeking FDA guidance for future development and potential approval of this formulation.

MediciNova, a clinical-stage biopharmaceutical company, announced positive results from a subgroup analysis of its Phase 2 clinical trial for MN-001 (tipelukast) at the International Diabetes Federation World Diabetes Congress 2022. The analysis revealed that participants with Type 2 diabetes mellitus (T2DM) experienced a greater reduction in serum triglyceride levels compared to those without T2DM (50.8% vs 17.8%). Additionally, significant increases in HDL levels were noted in the T2DM group. MediciNova is pursuing further trials to evaluate the efficacy of MN-001 in patients with T2DM and hypertriglyceridemia.